Not applicableStudy completedNCT03841266What this trial is testingRecurrence Risk Evaluation by 21-gene DetectionWho this might be right forRelationship and Consistency Analysis Xijing Hospital 220
Not applicableUnknownNCT05167643What this trial is testingH (Trastuzumab or Biosimilar) Combined With CDK4/6 Inhibitor + AI±OFS in the Treatment of HR+HER2+ Advanced Breast Cancer Efficacy and Safety: a Chinese Multi-center Real World StudyWho this might be right forAdvanced HR+ HER2 Negative Breast Carcinoma Tianjin Medical University Cancer Institute and Hospital 40
Testing effectiveness (Phase 2)Active Not RecruitingNCT04225117What this trial is testingEvaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)Who this might be right forLocally Advanced or Metastatic Malignant Solid Tumors Astellas Pharma Global Development, Inc. 329
Testing effectiveness (Phase 2)Study completedNCT02403271What this trial is testingA Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid TumorsWho this might be right forNon-Small Cell Lung CancerBreast CancerPancreatic Cancer Pharmacyclics LLC. 124
Large-scale testing (Phase 3)Looking for participantsNCT07294508What this trial is testingEvaluate HLX22 in Combination With HLX87 in Patients With HER2-Positive Recurrent or Metastatic Breast CancerWho this might be right forHER2 + Breast Cancer Shanghai Henlius Biotech 706
Testing effectiveness (Phase 2)Looking for participantsNCT07191717What this trial is testingImlunestrant and Abemaciclib for the Treatment of Estrogen Receptor Positive Breast Cancer in Patients With Minimal Residual Disease, MIRI TrialWho this might be right forAnatomic Stage I Breast Cancer AJCC v8Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8+3 more Jonsson Comprehensive Cancer Center 42
Testing effectiveness (Phase 2)Study completedNCT00436566What this trial is testingDoxorubicin and Cyclophosphamide Followed By Trastuzumab, Paclitaxel, and Lapatinib in Treating Patients With Early-Stage HER2-Positive Breast Cancer That Has Been Removed By SurgeryWho this might be right forBreast CancerCardiac Toxicity Mayo Clinic 122
Testing effectiveness (Phase 2)UnknownNCT01709370What this trial is testingLetrozole and CDK 4/6 Inhibitor for ER Positive, HER2 Negative Breast Cancer in Postmenopausal WomenWho this might be right forER Positive, HER2 Negative Breast Cancer Organisation for Oncology and Translational Research 45
Testing effectiveness (Phase 2)UnknownNCT05512780What this trial is testingDalpiciclib Combined With Letrozole in Neoadjuvant Treatment of Stage Ⅱ-Ⅲ HR-positive/HER2-negative Breast CancerWho this might be right forSolid Tumor Hebei Medical University Fourth Hospital 30
Not applicableUnknownNCT06174259What this trial is testingInfluence of Intermittent Fasting on Locally Advanced Breast Cancer PatientsWho this might be right forLocally Advanced Breast CancerIntermittent Fasting Menoufia University 66
Testing effectiveness (Phase 2)Active Not RecruitingNCT04561362What this trial is testingStudy BT8009-100 in Subjects With Nectin-4 Expressing Advanced MalignanciesWho this might be right forUrinary Bladder NeoplasmTriple Negative Breast NeoplasmsHormone Receptor Positive, HER2-negative Neoplasms+5 more BicycleTx Limited 329
Not applicableActive Not RecruitingNCT07541703What this trial is testingIndependent, External, Blinded Retrospective Validation of an AI-based Prognostic Assay in ER-Positive/HER2-Negative Early Breast CancerWho this might be right forBreast CancerEarly Breast CancerER-Positive HER2-Negative Breast Cancer Spotlight Medical 2,200
Testing effectiveness (Phase 2)UnknownNCT03906669What this trial is testingA Window of Opportunity Study of Pre-operative Endocrine Therapy With and Without Prometrium in Postmenopausal Women With Early Stage Breast Hormone Receptor Positive (HR+) Human Epidermal Receptor 2 Negative (HER2-) Breast Cancer.Who this might be right forEarly-stage Breast CancerHormone Receptor Positive Tumor St Vincent's Hospital 200
Large-scale testing (Phase 3)UnknownNCT01622361What this trial is testingPremenopausal Patient With Hormone Responsive, HER2 Negative, Lymph Node Positive Breast CancerWho this might be right forBreast Cancer Asan Medical Center 290
Testing effectiveness (Phase 2)Study completedNCT02988986What this trial is testingTAK-228 Plus Tamoxifen in Patients With ER-Positive, HER2-negative Breast CancerWho this might be right forEstrogen Receptor Positive Breast Cancer The Methodist Hospital Research Institute 28
Large-scale testing (Phase 3)Looking for participantsNCT07541079What this trial is testingA Study Evaluating Adherence, Tolerability, and Patient Reported Outcomes of Giredestrant in Participants With ER+/HER2- Early Breast Cancer Who Are Intolerant to Adjuvant Aromatase Inhibitor Therapy (novERA Breast Cancer)Who this might be right forEarly Breast Cancer Genentech, Inc. 300
Not applicableLooking for participantsNCT06930859What this trial is testingNon-interventional Study to Assess the Effectiveness and Safety of Ribociclib in the Adjuvant Therapy of Hormone Receptor Positive (HR+) HER2-negative Stage II and III Breast Cancer in Real Clinical Practice in RussiaWho this might be right forBreast Cancer Novartis Pharmaceuticals 2,766
Testing effectiveness (Phase 2)Looking for participantsNCT05816655What this trial is testingComparison of Clinical Efficacy Between Letrozole + Ribociclib and Fulvestrant + Letrozole + Ribociclib in Hormone Receptor Positive, HER2 Negative Metastatic Breast CancerWho this might be right forMetastatic Breast Cancer Korea University Guro Hospital 202
Large-scale testing (Phase 3)Active Not RecruitingNCT04711252What this trial is testingA Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced DiseaseWho this might be right forER-Positive HER2-Negative Breast Cancer AstraZeneca 1,370
Testing effectiveness (Phase 2)Study completedNCT03007992What this trial is testingMetronomic Treatment With Daily Oral Vinorelbine as First-line Chemotherapy in Patients With Advanced/Metastatic Hormone Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Breast CancerWho this might be right forMetastatic Breast Cancer Johannes Gutenberg University Mainz 9